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ABSTRACT
This thesis describes how a 55% reduction in error rate and a 92% decrease in cycle-time
were achieved in a batch production records process in a biotech manufacturing facility
by utilization of value-stream mapping. The project focuses on careful analysis of the
current state of a batch production record review process, including an in-depth value
stream map, to identify sources of rework and waste in the current process. Analysis of
the value stream map led to the recommendation of real-time review of the
documentation by Quality Assurance and Manufacturing on the production floor,
enabling significant cycle-time and error rate improvements.
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CHAPTER 1: INTRODUCTION
1.1 INTRODUCTION TO BATCH PRODUCTION RECORDS
A Batch Production Record (BPR) is a document which tracks all critical aspects of
manufacturing. During production, the BPR serves as a recipe that the operator follows in
order to correctly manufacture the production. Post-production, the BPR serves as a
single, stand-alone document that stores all critical information about batch processing. A
typical BPR in the biopharmaceutical industry will include critical information such as
amount of active pharmaceutical ingredient added to the batch, batch yield, and other
critical parameters.
Batch Production Records are required by various regulatory bodies. A brief discussion
of the Federal Drug Administration (FDA) and European Medicines Agency (EMEA)
requirements are discussed in Sections 1.1.1 and 1.1.2.
1.1.1 FDA REQUIREMENTS
According to the FDA Code of Federal Regulations (CFR) Section 211.188 on Batch
Production and Control Records,
"Batch production records and control records shall be prepared for each
batch of drug product produced and shall include complete information
relating to the production and control of each batch. " (1)
Drug manufacturers are required to provide documentation that each significant step in
the manufacture, processing, packing or holding of the batch was accomplished, which
includes but is not limited to the following: dates, identities of components, weights and
measures, actual yields, and identification of persons performing and checking each
significant step (1).
The Code of Federal Regulation also specifies guidelines for Production Record Reviews.
In Section 211.192, the CFR states:
"All drug product production and control records.... shall be reviewed
and approved by the quality control unit to determine compliance with
all established, approved written procedures before a batch is released
or distributed." (1)
In summary, the FDA expects drug manufacturer to provide comprehensive
documentation of all the critical aspects of manufacturing, and then have this
documentation reviewed and approved by the quality control unit prior to drug
release into the marketplace.
1.1.2 EMEA REQUIREMENTS
The European Medicines Agency has similar requirements for production records. Part 1,
Chapter 4, Section 4.17 Batch Processing Records of the EU Guidelines to Good
Manufacturing Practice Medicinal Products for Human and Veterinary Use, Volume 4,
states:
"A Batch Processing Record should be kept for each batch processed. It
should be based on the relevant parts of the currently approved
Manufacturing Formula and Processing Instructions. The method of
preparation of such records should be designed to avoid transcription
errors. The record should carry the number of the batch being
manufactured." (2)
Section 4.14 in Manufacturing Formula and Processing Instructions states that the
Manufacturing Formula, which provides the basis for the Batch Processing Record, must
include the product name, product code, pharmaceutical form, strength of the product and
batch size, starting materials and amounts, and final expected yield (2).
Likewise, in Section 4.15 Manufacturing Formula and Processing Instructions indicates
that the Processing Instructions (which also provide the basis for the Batch Processing
Record) must include several items, including the equipment to be used, detailed stepwise
processing instructions (e.g. checks on materials, pre-treatments, sequence for adding
materials, mixing times, temperatures), and the instructions for any in-process controls
with their limits (2).
Additionally, in Part 1, Chapter 1, Section 1.1 Quality Assurance of EU Guidelines to
Good Manufacturing Practice Medicinal Products for Human and Veterinary Use,
Volume 4, it is stated:
"Medicinal products are not sold or supplied before a Qualified Person
has certified that each production batch has been produced and controlled
in accordance with the requirements of the Marketing Authorisation and
any other regulations relevant to the production, control and release of
medicinal products" (3)
In summary, the like the FDA, the EMEA expects drug manufacturers to
provide documentation of all the critical aspects of manufacturing for each
batch, and then have this documentation reviewed and approved by the quality
control unit prior to drug release into the marketplace. Unlike the FDA, the
EMEA specifically requires the final product release to be performed by a
Qualified Person, who is a person who has relevant training and has passed
appropriate examinations for the role.
1.2 PROJECT DRIVERS
The biotechnology industry faces many current challenges. Some of these challenges
include a shift toward "tailored therapies" (and away from traditional blockbuster
models), the threat of generics (or bio-similars), diminishing pipelines, and pressure from
consumers and governments to drive down costs while maintaining quality. These
pressures create a strong justification to focus on streamlining internal processes in order
to drive down costs and improve quality.
This project focuses specifically on improving the Batch Production Record process for a
specific biopharmaceutical drug process at Novartis Vaccines and Diagnostics.
Biopharmaceutical companies rely on the Batch Production Record to serve as a stand-
alone piece of documentation to prove that a batch was made correctly. Additionally, the
BPR has specific regulation on its content. Not surprisingly, the process of executing, and
approving a Batch Production Record process can be complex and time-consuming. It is
even more time consuming if there are errors in its completion.
There are two main drivers for this project: improving the efficiency and compliance of
Batch Production Records. Ideally, batch documentation should be done correctly first
time, and it should be done quickly. The two are intrinsically linked; improvements in
one area cannot be made without impact in the other.
1.2.1 EFFICIENCY DRIVERS
Theoretically, the batch record will have an optimized minimum cycle-time, allowing the
product to reach the customer as quickly as possible.
There are several reasons why this goal is hard to reach. Prior to manufacturing, BPR
documentation must be assembled and verified by both production and manufacturing;
these are time-consuming activities which can impact the start of production.
Additionally, there are many steps following manufacturing, such as materials
reconciliation and verification of data that prevent the documentation from being
completed at the time that production of a batch is completed. Also, internal procedure at
Novartis Vaccines and Diagnostics requires production personnel to review and sign the
documentation after completion. Finally, as discussed in 1.1.1 and 1.1.2, regulatory
guidance requires a post-production approval of the documentation by quality to ensure
that any errors in the documentation or calculations are found and addressed before the
product is delivered to the patient. All of these activities add time to the overall
production cycle-time, extending the time between the completion of production and the
time the batch can actually be released to on the market.
At Novartis Vaccines and Diagnostics, the overall production cycle-times for batch
records can vary widely: in some cases, the cycle-times can be several months. It is
understood that improving the efficiency of the process (and thus, reducing cycle-times)
can create an opportunity to deliver vaccines to patients faster, which saves the company
money on inventory holding costs, prevents possible inventory expiry, and helps meet
customer order requests.
However, many of the 'barriers' to faster cycle-times are due to regulatory requirements
as well as internal standards to ensure safety and efficacy of the vaccine. The desire to
drive down cycle-times must be tempered with a firm understanding of the quality
requirements.
1.2.2 COMPLIANCE DRIVERS
In addition to the desire to drive down cycle-time, there is a strong driver to improve
documentation compliance. The batch record serves as a stand-alone document, intended
to adequately describe all components, calculations, and manufacturing steps performed
in order to manufacture a batch. Additionally, in a regulatory audit, a production batch
record could be reviewed by a regulatory agency. In this case, the manufacturer would
prefer to deliver a document free of errors than one riddled with errors, notes and
corrections. As such, it is desired for the document to be filled out by operators without
any errors; we can refer to the concept of execution without any errors as "Right First
Time". There is a strong driver to simplify the documentation in order to ensure that the
operators fully understand the documentation, and are able to execute the document
correctly each and every time they utilize the document.
The benefit for "Right First Time" (RFT) is two-fold. First, RFT improves compliance by
delivering documents that are free of errors, improving the overall quality of
documentation and audit preparedness. Additionally, batch records which contain no
errors do not require re-work, which saves time and resources. If errors are found after
manufacturing, corrections may require additional time and resources to investigate the
error and supply an adequate correction. These errors create a burden on resources;
additionally these errors can extend the batch record cycle time, which can mean that the
product may take longer to reach the patient.
Again, the desire to simplify the document must be tempered with regulation; all critical
steps must remain in the documentation, so an understanding of the regulation is required
when working to streamline the documentation process.
1.3 PROBLEM STATEMENT
In their book Operations Strategy: Competing in the 21" Century, Beckman and
Rosenfield state that "the essence of lean thinking is reducing waste and making
operations as efficient and as consistent as possible. " (4). Beckman and Rosenfield also
discuss that process efficiency is not the only benefit of lean thinking; other additional
benefits include:
* Reduced lead times through lower work-in-process inventory
" Problem solving and quality improvements driven by needs to reduce waste and
variability
* Team building and cooperation by linking different steps
Thus, we can see that conceptually, the application of lean tools can help us achieve our
overall goals to improve documentation efficiency (by helping to reduce cycle-times) and
compliance (by improving RFT consistency). Furthermore, implementation of lean
thinking to this process may also result in additional benefits to the process team, such as
improve team cooperation and continuing improvement.
This project seeks to evaluate the benefit of implementation of lean thinking to a
documentation process within the biopharmaceutical industry. Specifically, the project
seeks to evaluate the impact of value-stream mapping (VSM) on documentation
processes in order to decrease cycle-times. It also seeks to evaluate the benefit of utilizing
value-stream mapping and other lean tools on regulated documentation in order to
improve compliance and "Right First Time" rates. Additionally, the project seeks to
evaluate methods of implementation of operational excellence, or lean, projects within a
highly-regulated industry.
1.4 APPROACH
The general approach for this project was in alignment with Novartis Vaccine and
Diagnostics' Innovation, Quality, and Productivity (IQP) framework of "Scope, Seek,
Solve, Sustain", which will be discussed in more detail in section 2.4. The following
figure outlines the basic project approach.
Table 1: Project Approach
SCOPE Define the scope
Determine appropriate key resources
Interview and observe to understand current state
Create VSMof current state process
Set project goals
SEEK Brainstorm root causes
SOLVE Brainstorm & classify solutions
Select recommendations
Implement improvements
SUSTAIN Measure against success criteria
1.5 THESIS OVERVIEW
Chapter One provides a basic overview of batch records, and describes the problem
statement and project drivers for this thesis.
Chapter Two presents background about the vaccines industry and Novartis Vaccines
and Diagnostics (NVD). It also describes the lean frameworks institutionalized at NVD.
Chapter Three details the methodology for data collection and the analysis of the
current state. It details how opportunities for improvement were observed, prioritized,
and implemented. This chapter also discusses the results of this implementation.
Chapter Four details conclusions of the thesis, recommendations, and possible future
activities for NVD.
CHAPTER 2: BACKGROUND
2.1 BIOPHARMACEUTICAL INDUSTRY BACKGROUND
In recent years, the term "biopharmaceutical" has been applied to a variety of products.
Although there is still some debate and ambiguity over the term, biopharmaceuticals are
generally considered to be a pharmaceutical inherently biological in nature and
manufactured using biotechnology (5).
The biopharmaceutical industry is considered to be a specialized portion of the broader
pharmaceutical industry. Biopharmaceutical products (also known as "large molecules"
or "biotech") are derived from biological sources, and include proteins, nucleic acids, and
cell products. Typical biopharmaceutical drugs are produced by the fermentation of
microbial cells (such as E.coli or yeast cultures), mammalian cell cells or plant cells. This
can be contrasted with the larger pharmaceutical ("small molecule" or "pharma")
industry, which generally produces medicines via chemical synthesis processes.
The first biopharmaceutical product was biosynthetic insulin made via recombinant DNA
technology. The drug, produced by Eli Lilly and marketed under the trade name
Humulin, was approved in 1982. As of 2008, there were over 350 different marketed
biopharmaceutical products (5).
While biopharmaceuticals are considered to be a subset of pharmaceuticals, there are
significant differences between the two. In general, small molecule drugs are made up of
a small number of atoms; in contrast, biopharmaceutical molecules can have thousands of
atoms, and are complex and difficult to fully visualize and understand. Small molecule
drug products and can be produced with high consistency using standardized chemical
processes. However, these sorts of chemical processes frequently utilize heat or solvents
that would kill most biopharmaceutical molecule, which must be made using more
complex manufacturing processes. Most small molecule drugs are derived from chemical
precursors; due to the ability to replicate chemical processes, it is possible to replicate
batch after batch of nearly identical drug product. However, in the case of
biopharmaceuticals, the drug source and manufacturing process are biological in nature,
which allows inherent randomness and complexity to complicate the manufacture of
biopharmaceuticals (5).
Thus, while biopharmaceuticals are a subset of pharmaceuticals, biopharmaceuticals are
clearly a more inherently complex and complicated process, which creates additional
challenges when working to improve biotech processes.
2.2 VACCINES MANUFACTURING BACKGROUND
Vaccines are a specific biopharmaceutical product intended to improve a patient's
immunity to disease. Vaccines are often manufactured from weakened or dead forms of
an infectious microbe. While this weakened or dead form should not harm the patient, but
will induced a response from the immune system to create antibodies or other
immunogenic responses which will protect the patient from that specific microbe if is
encountered in the future. (6)
Vaccines are actually some of the oldest modem-day medicines; vaccination was
pioneered by Edward Jenner in 1796, when he famously inoculated an 8-year old boy
against smallpox (7).
Modem day vaccines are typically derived from dead or inactivated organisms. Vaccines
may be monovalent (meaning they protect the patient against one strain of a disease) or
multivalent (meaning they protect the patient against multiple strains).
In addition to some of the challenges faced in the production of biopharmaceuticals as
discussed in section 2.1, there are additional challenges specific to the vaccines industry.
In contrast to other types of medicines, vaccines are somewhat unique in that they are a
prophylactic treatment given to perfectly healthy patients in order to maintain health, as
opposed to therapeutic medicines which seek to cure patients who are already sick.
Because vaccines are a preventative care medication, there is a lower willingness to pay
for vaccines than for therapeutic medications. As a result, vaccines typically have a much
lower margin than other pharmaceutical or biopharmaceutical products (8).
In effect, the vaccines industry utilizes complex, heavily regulated processes in order to
produce a low-margin product (relative to other medicines). For this reason,
implementation of operational excellence in order to improve efficiency and compliance
is of utmost importance and have potential for significant impact.
2.3 NOVARTIS V&D BACKGROUND
Novartis International AG is a large multinational pharmaceutical firm based in Basel,
Switzerland. In 2008, Novartis International AG had over $41 billion in sales, and
employed over 96,000 employees worldwide (9). Novartis provides a full-range of
healthcare products, and is generally divided into four separate divisions:
Table 2: Novartis International AG Divisions (10)
Vaccines and
Pharmaceuticals Sandoz Consumer Health
Diagnostics
Human vaccines and Readily 
available
Patent-protected diagnostic tools to Generic products, including
over-the-counter drugs,




The following figure showcases revenue by division for 2008.






The Vaccines and Diagnostics division is currently the smallest division, with
approximately 4% of sales and just over 4,000 employees (9).
Novartis Vaccines and Diagnostics, in addition to being the smallest division, is also the
newest within the Novartis family. The division was created in 2006 after Novartis
acquired Chiron Corporation.
Chiron Corporation was founded in 1981 in Emeryville, California, and their business
focused on biopharmaceuticals, vaccines, and blood diagnostics. Chiron expanded
significantly in 1998 with the acquisitions of vaccines manufacturers Behring and Sclavo.
They expanded again in 2003 with the acquisition of vaccines manufacturer PowderJet
(12).
In 2004, Chiron was the focus of much negative attention when their license for one of
their influenza vaccines, Fluvirin, was suspended due to quality concerns, leading to a
vaccine shortage. While the license was reinstated in 2005, Chiron was in a
compromised financial position, and was acquired by Novartis in 2006. The vaccines and
diagnostics portions of Chiron's business became the newly created Novartis Vaccine
and Diagnostics division, and Chiron's biopharmaceuticals were absorbed into Novartis'
Pharmaceuticals division.
This history is not only interesting, it is also an important piece of understanding the
culture of Novartis Vaccines and Diagnostics. While Novartis Pharma is a large, well-
established company, NVD is new fledgling member of the Novartis family. The division
was created recently, and was created as an acquisition of a struggling company (which
itself had been created as a result of acquisitions). As such, the NVD sites continue to
undergo great cultural change, in order to create one cohesive culture across its sites.
In their paper Managing Post-Acquisition Cultural Change: An Acquired Company's
Perspective, Zueva and Ghauri state that much of the literature currently available on
merger and acquisition (M&A) failures indicate that these failures are a most often the
result of cultural differences between the combined companies. These failures can be
caused because the different cultural frameworks utilized at the acquiring and target
companies can cause misunderstandings between employees, attributional errors, and
ultimately lower performance. The authors state:
"beliefs and assumptions shared by the respective employees of the
acquirer and target . .. often represent deep-rooted differences between
the combining firms that can lead to challenges... all acquisitions will be
confronted with cultural differences that need to be clarified and managed
effectively to avoid cultural conflict." (13)
Thus, we can see that cultural differences between sites are one major concern for
acquired companies. In an effort to create a continuous, cohesive culture across all of its
sites, NVD has undertaken many initiatives aimed at standardizing processes across its
sites. One of the major initiatives aimed at standardization within NVD is the
implementation of operational excellence via the Innovation, Quality and Productivity
(IQP) program, which is described in the next section.
2.4 INNOVATION, QUALITY, PRODUCTIVITY (IQP) AT
NOVARTIS V&D
The Innovation, Quality and Productivity (IQP) program is an operational excellence
framework that is utilized across Novartis International AG.
According to the internal Novartis Vaccines and Diagnostics' IQP website, IQP is a
coordinated system of process improvement across the Vaccines & Diagnostics that
stresses:
. A disciplined and rigorous, world-class project management system for all
process improvement initiatives
. Focus on continuous improvement
. Cutting-edge business tools and problem solving processes
. Cross-functional best practice sharing and collaboration (14)
Within Novartis Vaccines and Diagnostics, there are specific resources within the
Technical Operations ("TechOps") organization who are dedicated to implementation of
lean initiatives across the sites, as well as training others within the TechOps organization
about operational excellence.
According to Matt Stober, the Global Head of NVD Technical Operations (15):
"Novartis Vaccines & Diagnostics has significant challenges in front of us
to launch 5 new vaccines and transform the company into a $4-5 billion per
year business by 2011. In order to achieve these goals operational
excellence will be a critical component of running our business going
forward."
Thus, although Novartis Vaccines and Diagnostics is a relatively "new" company,
they are aggressively working to incorporate operational excellence into the fabric
of the company. I observed the following statement in some IQP training
materials:
"IQP is not another program or initiative ... It is an attitude - a
'data-driven' continuous improvement mindset (16)"
Thus, the program works on the premise of instilling a cultural mindset towards
continuous improvement. However, the IQP program does utilize a set of tools
and frameworks in order to implement projects. The overarching framework
utilized is "Scope, Seek, Solve, Sustain", which is detailed in Figure 2 below.




This project relied heavily on the "Scope, Seek, Solve, Sustain" framework, and also
focused on driving cultural change to adopt a more "data-driven continuous improvement
mindset" at the site.
CHAPTER 3: BATCH RECORD PROCESS
The project followed the general IQP framework of Scope, Seek, Solve and then Sustain.
Each portion of the project will be discussed separately in Chapter 3.
3.1 SCOPE PHASE
The initial phase of the project focuses on the "Scope" phase of the IQP framework,
which includes defining project scope and evaluating the current state.
3.1.1 DEFINING PROJECT SCOPE
Per the IQP method, we initially focused on determining the appropriate scope. The
project site has a range of manufacturing capabilities, including bulk processing, aseptic
formulation and filling, and secondary packaging functionality. The site supports a range
of products, including flu, meningitis, and other vaccines.
It was determined to focus the project on one portion of the manufacturing process of a
single product. The product is an important product in the NVD portfolio; thus, having an
efficient and compliant BPR process for this product is of utmost importance to the
company and to timely delivery to the patient.
3.1.2 UNDERSTANDING THE CURRENT PROCESS
To move forward with the project, we must first understand the process. According to
Beckman and Rosenfield in Operations Strategy: Competing in the 2 1" Century, high-
level process maps, or "30,000 foot overviews", can be used to scope new projects and
set boundaries (4). In this section, we will discuss such a high-level overview, which
allowed us to select the critical areas to focus and analyze during the course of this
project; later, in section 3.1.5, we will utilize a more detailed value-stream map in order
to fully analyze the process and create recommendations.
We began the process of drawing project boundaries with a high-level process overview.
Figure 3 below depicts the general BPR flow observed at Novartis Vaccines and
Diagnostics.
Figure 3: Basic Documentation Flow for BPRs
Frna Batch QA~dcto Prtoduction
Approval Review
Quality Assurance (QA) assesses the pre-approved BPRs via an electronic system. They
print out BPRs for each batch by inserting specific batch data (lot number, product code,
etc) into a standard, approved master BPR.
Then QA reviews the printed BPR. QA checks for any errors, such as missing pages.
Then, QA forwards the BPR to Production. Production checks the BPR for errors. In
some cases, Production adds production attachments to the BPR.
Once production is ready to start the actual batch processing, Production personnel take
the BPR into the processing area and execute the document as production occurs.
Portions of the BPR related to batch reconciliation, post-production cleaning, and other
activities are sometimes executed after production is completed. After production ceases
and the BPR is fully executed, Production reviews the BPR. The check is intended to
ensure the BPR is filled out completely and correctly.
Next, the BPR is approved by the Production Approver, who has specific training in
order to provide manufacturing approval of the document.
Next, QA reviews the BPR, and checks that the BPR is filled out completely and
correctly. Finally, a QA Approver does a final check of the completeness of the
document, and gives final QA approval of the document.
Next, QA forwards the BPR to Batch Release (it should be noted that this step is outside
the scope of this project). Batch Release personnel ensure that all analytical testing of the
batch has been executed in accordance with all applicable FDA and EMEA regulation
and all results are within specifications to ensure the batch is safe and effective. Finally,
Batch Release does a final check of the document, and then approves the BPR. At this
point, Batch Release personnel release the batch to the market.
3.1.3 METRICS SELECTION AND DATA COLLECTION
Section 3.1.2 provided an overall view of the batch production records review processes
across Novartis. The next step for the project team is to establish a detailed process view
of our selected process. However, before we can begin to establish this detailed process
map, we must define the important criteria and/or metrics for this project, so that we can
collect data and define baseline historical metrics as a comparison point.
Additionally, we realize the importance of defining the overlying metrics with which to
measure the current state, as well as the future state. Careful selection of these metrics is
important, because these are the metrics we will measure ourselves against in the future.
This project focuses on compliance and efficiency of the BPR process, and it naturally
evolved that our major metrics would be ones directly related to efficiency and
compliance. The two most important metrics for this project are defined as cycle-time
and Right First Time rate.
3.1.3.1 Cycle Time Metric
Overall, the cycle-time of the BPR can be expressed as the time from when the BPR is
created until final approval by QA. However, this metric can be broken down further in
order to gain greater clarity. The general BPR process can be split into four segments:
pre-production, production, post-production, and final release, as shown in Figure 4.
Figure 4: Breakdown of Cycle Time by Segment
Pre-Production: Pre-production cycle-time was evaluated. While conceptually a just-in-
time process for document preparation could be helpful, in actuality the process to create
and pre-approve BPRs is not time or labor intensive. Based on interviews, the
manufacturing area has not historically had any issues with downtime caused by BPRs
not being ready on time, etc. As such, the pre-production portion of the cycle time is not
considered an area of focus at this time.
Production: Production cycle-time was also evaluated. This project is focused on
improving documentation processes, not production processes. As such, the portion of the
cycle time associated with BPR execution during production is not in-scope, and was not
targeted in this project.
Post-Production: The area of focus for this project is the post-production cycle time. The
post-production portion of the cycle-time is considered the most critical, and has also
historically led to issues at the site. There are many reasons why the post-production
cycle time is critical. First of all, during production, the expiration date is established. For
vaccines, this expiration date can be quite short. Any delay after production cause by
BPR processes is simply time taken away from the sellable life of the product. Since
product cannot be released until the BPR is approved, any delays will lead to the
unnecessary and expensive storage of finished goods, which in the case of vaccines, are
expensive due to the required environmental controls required for their safe storage.
Finally, there is a compliance risk associated with post-production BPR review delays. If
an issue occurs on a batch that merits an investigation, this should be addressed
immediately in order to gain information while it is still readily available, as well as to
confine the issue to the smallest number of batches. Since the discovery of such issues
occurs during the BPR review, this review should happen as quickly as possible to ensure
issues are addressed appropriately and immediately.
Final Release: Finally, the final release portion of the process was evaluated. At
Novartis, this step is performed by an independent group of Quality Assurance personnel,
who review all applicable laboratory assays and other information to ensure the product
can be released to the market. As this step is performed by a separate team of resources, it
was considered out of scope for this particular project.
Thus, after careful consideration of all portions of the batch record cycle-time, we
determine that the most important cycle time metric for this project is the post-production
cycle time.
3.1.3.2 Right First Time Metric
Right First Time can be defined as a BPR which is executed fully with zero errors in
documentation. However, this definition is still somewhat vague; we must also determine
at which point in the process we will check for errors and determine if the batch record is
Right First Time. Historically, the site has checked for Right First Time rates when
Quality Assurance first views the documentation. This means that if a batch record had
several errors which were discovered immediately in production and corrected
adequately, it could still be classified as Right First Time as long as no errors were found
in QA review. Likewise, a batch which had a single error which was not discovered until
Quality Assurance made their final review would not be considered Right First Time.
For the sake of consistency with current norms within manufacturing, we decided to
utilize this existing definition of Right First Time, in which only errors discovered in the
QA review or approval steps are classified as errors which impact RFT.
In addition to Cycle-Time and Right First Time, the team discussed also evaluating a
measure of efficiency of the system, such as Percent Value-Added Time. However, in
Quick Response Manufacturing: A Companywide Approach to Reducing Lead Times,
Suri Rajan mentions that most measures of efficiency work to counter lead time reduction
(17). He encourages teams to focus less on measures of efficiency, and more on the true
end goal: reduced cycle-times. Thus, we were hesitant to utilize a measure of efficiency
in our evaluations. We discussed what was truly important to the project team and
sponsors. In the end, we ultimately desired a process that allowed products to get to
patients faster and with less errors. Thus, while we realized that improvements to system
efficiency might be a solution to reach these goals, we understood that measuring and
improving system efficiency metrics (such as Percent Value-Added Time) was not a
primary goal of this project. Thus, we decided to focus exclusively on Cycle-Time and
Right First Time rates.
3.1.4 TEAM AND CHARTER
Once clear scope objectives had been set, it was important to select and begin engaging
the team. The team members were selected based on expertise as subject matter experts,
as well as knowledge of English since our project occurred in a non-English speaking
nation. A cross-functional team of Quality Assurance reviews and approvers,
manufacturing reviewers and approvers, as well as quality assurance and manufacturing
leadership were selected as team resources.
A charter was developed to outline the objectives of the project (to improve cycle-times
and Right First Time rates), as well as a general project timeline of six months to
completion of objectives.
3.1.5 CURRENT STATE VALUE STREAM MAP
The first major goal of the project was to adequately understand the current process. At
the outset, the team has many theories about why cycle-times were long and error rates
were high; these theories ranged from too few resources, to difficulties in prioritization,
to challenges in obtaining appropriate documentation to close the BPR. While there were
many theories and assumptions, it was not clear what was, in fact, the true root cause of
the issues at hand. The team utilized Value-Stream Mapping in order to truly understand
the current process before moving forward with solutions.
According to Beckman and Rosenfield in Operations Strategy, Competing in the 21"'
Century, value-stream mapping is a process-mapping tool which aims to identify process
improvements by graphically mapping out the process (4). Value-stream maps can
identify wasted movements and unnecessary steps.
Thus, we begin the process of graphing out the BPR process at hand. For this project,
historical data were utilized. In Learning to See, Rother and Shook strongly encourage
value-stream mapping to be done exclusively with directly observed, real-time data (18).
However, in our case, cycle-times were in the weeks and due to the relatively short
project timeline (six months), we were not able to gather significant real-time data for our
current state analysis. Data were mined from both Quality Assurance and Manufacturing
groups, who tracked each batch. Generally, each group tracked when they received the
document, and when they approved the document. By merging data from the two groups,
we were able to better understand the timing of the various parts of the process. One sees
that a barrier in this analysis is the silo nature of data collection; significant improvement
could come from a holistic view of data collection.
Additionally, we interviewed many documentation process experts, namely the reviewers
and approvers responsible for moving documents through the process, in order to
understand how long each review step actually took and to better understand the process
flow.
From this we were able to start building a picture of how long a specific documentation
step actually took (considered the value-added time), as well as the average wait time
between process steps (considered non-value added time).
In our case, we had significant data for approximately seven months (January 2009 - July
2009). However, there had been a significant process change for the area in early 2009;
the area organization was re-structured into a more cross-functional, matrix-based
structure which had improved many processes, including the BPR process. The data
indicated this restructuring had positively impacted cycle times and error rates. Since the
re-structuring was permanent, we considered the recent successes sustainable. Thus, we
decided to utilize only the most recent data from July 2009 in order to create our baseline.
These data from July 2009 were used to construct a detailed Value-Stream Map of the
current BPR process. The Value-Stream Mapping was an iterative process; we created a
draft and presented to the team, who provided feedback and comments. Initially, there
was push-back to some of the data presented; we discussed to reach a process map that
was in alignment with both the data, as well as resources' expert testimony. Additionally,
we added several process steps over time in order to truly capture the process.
The creation of the chart was an iterative process, and we felt that we could create nearly
endless iterations if we continued to dig deeper and deeper into the data. However, The
Lean Six Sigma Pocket Toolbook cautions against getting so wrapped up in creating a
perfect flowchart that you delay the start of value-add work on the project (19). Thus,
after several iterations, we created a final version of the Value-Stream Map. While not
yet perfect, this map was complete enough that Quality, Manufacturing, and IQP
representatives agreed the map reflected the current process to a degree of clarity that
would allow us to move forward with decisions and recommendations on improvement.
This final Value-Stream Map is presented in Figure 5.
Figure 5: Value- Stream Map of Process (Current State)
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On this map, the boxes represent process steps. The lowered values directly below the
boxes indicate activity times, or value-added time. The raised values between steps
represent wait times, or non-value added time. It should be noted that the historical data
reviewed allowed us to establish the average time between process steps; however, the
actual activity (or value-added) times were estimated based on interviews with the
resources who perform these steps.
Upon creation of the value stream map, we discovered two major differences between the
actual process and the process outlined in section 3.1.2. First, the actual process had an
additional review step, called the "GMP review". GMP review is an additional
Production review which is targeted at "completion" errors, or errors that are the result of
a missing signature, missing attachment, or otherwise incomplete documentation.
Second, the process required an additional "BPR Closure" step. BPR closure is different
from approval. Once the document is reviewed by QA, any errors were addressed, and
the document is found satisfactory, the document is considered closed. However, the
process required that a set, or bundle, of BPRs be reviewed together, so the BPR would
not be formally approved until the entire bundle was completely reviewed. It was noted
that since these additional steps are not explicitly required by the regulatory authorities, it
may be possible to remove them from the process flow.
3.1.6 PROJECT BASELINE AND GOAL SELECTION
With the Current State Value Stream Map, we can establish a baseline for our selected
criteria.
The post-production cycle time was determined by summing the average time of all
activities from the point when production stops until the batch is delivered to batch
release personnel. This rate is based on calendar days (not work days or shifts).
The Right First Time rate is the percentages of batches which are delivered to Quality
Assurance which have no errors (and can be thought of as the inverse of the re-work rate
at this process step). The baselines are shown in Table 3.







In order to select appropriate project goals, we considered feasibility and necessity.
Expected advances in assays used in final product release are an external driver to
significantly decrease our cycle-time. Additionally, while the team and site generally
considered the Right First Time rate to be good, we felt there was room for improvement.
Additionally, we wanted to set both project goals that we expected to reach within the
confines of the project, as well as "Blue Sky" goals, intended to be a stretch goal for the
team in the future. Table 4 shows the established Project Goals and Blue Sky Goals.
Table 4: Project and Blue Sky Goals
In summary, the project team focused on targeting moderate RFT improvements, and
aggressive improvement in cycle-times.
3.1.7 ANALYZING THE CURRENT STATE VALUE STREAM MAP
We carefully analyzed the Value-Stream Map to understand the major sources of delay
and re-work. When examining delay times between process steps, we focused our efforts
after production, in alignment with our desire to drive down post-production cycle times.
Goal Blue Sky
Current Post-





3.1.7.1 Manufacturing Review and Approval
At first glance, we can see that there is a delay of at least one day between all post-
production steps, including the various manufacturing review and approval steps.
First, we can see that it takes approximately 1.0 days for production to review the
document after production ceases. After this review, it takes approximately 1.0 days
before the GMP review of the documentation is completed. After GMP review, the
document generally waits 0.9 days before it receives final approval. Finally, the
document generally waits 2.0 days after production approval before it is transferred to
quality assurance. The entire process has approximately 4.9 days of waiting time while
still in the production review stages. Thus, in the Seek phases, we sought to understand
the true root cause of these delays.
Additionally, we see that the value-added time for manufacturing review is a total of
3.5hrs (3 hours review, 15 minutes GMP review, 15 minutes manufacturing approval).
Thus, the 4.9 days of non-value added waiting time in this portion of the process is
certainly the bulk of the cycle-time.
3.1.7.2 Quality Assurance Review and Approval
Despite the 4.9 days of waiting time in the production review and approval steps, we see
that actually the bulk of the post-production cycle time occurs after the production
approval is completed.
On average, the document waits 8.5 days from when it is received by quality assurance
and the start of the QA review. Additionally, after the review has been started, it takes an
average of 9.0 days before the BPR has been fully reviewed, all errors have been
corrected, and the document can be considered "closed", or ready for final approval. We
see that there is approximately 11% rework at this step (indicating a RFT percentage of
89%); if an error is found on the document, it must go back to manufacturing for
correction, creating a re-work loop in the system.
Additionally, in this process area, some BPRs of related steps are bundled and reviewed
as a set; once the entire bundle of steps has been reviewed together, the entire bundle can
be approved. Once the entire bundle has been reviewed, the BPRs in that bundle are
considered closed. Finally, it takes 2.0 days from when the BPR is closed until it is
approved. In all, there are 19.5 days of wait time on average in the quality assurance
review and approval process.
In this portion of the process, there are 4.5 hours of value added time (4 hours for review,
15 minutes for closure, 15 minutes for approval). Much like the production review
portion of the process, the bulk of the cycle-time is made up of non-value added wait
time.
In the Seek phases, we sought to understand the true root cause of these delays. In
particular, we seek to understand and improve the wait times between production
approval and start of QA review, as well as the delay between the start of the QA review
and the BPR closure steps, as they each make up a significant portion of the overall cycle
time.
3.2 SEEK PHASE
3.2.1 DETERMINE POSSIBLE ROOT CA USES
Now that the major sources of wait time and rework in the system had been identified, we
focused on determining the root cause of these wait times and reworks.
3.2.1.1 Wait Time Root Causes
In this section, we will discuss the causes for wait time in both the production review and
approval portion of the cycle-time, as well as the quality assurance review and approval
portion of the cycle-time.
Production Review and Approval: In Section 3.1.7.1, we discussed the wait times
associated with the production review process. To truly understand the root cause, we
interviewed the resources who generally perform the review steps, and learned that the
major source of delay is a result of moving the document between different resources and
different locations.
The manufacturing itself occurs out in the production area of the specific production
building. After manufacturing is completed, the document must be moved from the
processing area to the production reviewers' desks. After this review is completed, the
document must be moved again to the desk of the GMP review, then moved again to the
desk of the manufacturing approvers, who are located in another building. A depiction of
this physical documentation movement process can be seen in Figure 6.
Figure 6: Geographical Representation of the BPR Review Process
Simulation Only. Does not depict actual Novartis building layout.
In Operations Management: Strategy and Analysis, Krajewski and Ritzman remark that
accessibility between co-workers can improve communication (20). The text instructs
that the proximity of works whose jobs require frequent interaction should be maximized.
We can see from Figure 6 that this proximity is not currently maximized, likely leading to
issues with communication and possibly cycle-time.
Because the steps are done in series and the document must travel from the production
floor, to a production support office, to an adjacent building housing production approval,
and finally to the quality control office, we can clearly see the multiple document hand-
offs and geographic distance impact manufacturing review and approval cycle time.
Quality Assurance Review and Approval: Next, we evaluate the delays associated with
the quality assurance review and approval portions of the process. Again, we interviewed
subject matter experts and evaluated the historical data to determine root causes. First, we
discover that the 8.5 day average wait once the document arrives in QA before it is
evaluated is mainly due to prioritization and resourcing issues. There are a limited
number of reviewers who support the reviews of batch records from many products from
multiple sites. Management sometimes requests certain products to be expedited at
certain times in order to meet critical deadlines. The seasonal nature of some of NVD's
product lines exacerbate this phenomenon. Some "less critical" products may be set aside
while the "expedited" orders are reviewed, which leads to extended cycle-times on less-
critical batches, extending the overall cycle-time.
Next, we investigated the reason for an average of 9 days of delay between when the
BPR review is started, and when it is considered complete (and the BPR is considered
ready for closure). The root cause for this delay is due to the batching of BPRs. Each
BPR is a portion of a larger production process. For example, BPR A, BPR B, and BPR
C might each detail an individual filtration step; to evaluate the filtration process as a
whole, you would need to evaluate all three BPRs. It is the practice of the QA group in
this area to evaluate a set of subsequent process steps together; in this example, they
would review BPRs A, B and C together. This practice, while perhaps providing a more
holistic review of the process, negatively impacts the cycle-time by requiring the
reviewer to wait for all the related BPRs before completing the review of any of the
component BPRs.
Additionally, in approximately 11% of all batches that undergo QA review, there is an
error noted. In this case, the batch record must be sent back to manufacturing for
correction, and then returned to QA. This clearly impacts the time between QA review
and QA approval steps. Root causes of this re-work will be discussed in Section 3.2.1.2.
Finally, we evaluate the delay time between QA review and QA approval. We can see
that as in the manufacturing portion of review and approval, the document must travel
within the quality assurance building from the reviewer's desk to the approver's desk.
This document hand-off likely impacts the cycle time of the quality review. Also, there is
only one full-time employee responsible for document approval, creating a resource
bottleneck that impacts the cycle-time. Per Figure 5, QA approval is estimated to take 15
minutes per BPR; this would mean that the QA approver could theoretically approve up
to 32 BPRs per eight-hour shift. The actual BPR load for this process is less than 32
BPRs per business day; however, the resource supports BPRs for multiple areas and sites,
as well as other quality functions, such as investigation support. As previously discussed,
there are shifting priorities in this work area; thus, we can see that since this resource
supports multiple areas, focus may shift away from BPRs from one area in order to
expedite BPRs from another area. With only one dedicated resource, we can easily see
that backlogs of BPRs could occur due to shifting priorities, or when the resource is on
vacation, sick, or otherwise out of the office.
Entire Process Review: After evaluating the individual delays, we reviewed the process
holistically and realized that the document must pass through five separate areas for
production review, GMP review, production approval, QA review, and QA approval, and
that these steps are all done in series. We note that even if each step is done in, say, one
day, we would still have an overall cycle time of five days, which is far from our Blue
Sky Goal of 24-hour cycle times. Thus, we conclude that the multiple reviews of the
document in series are a root cause of extended cycle times.
Additionally, we realized that while production occurs in multiple shifts across six days
of the week, the manufacturing and QA resources responsible for the review and approval
of BPRs typically work a standard Monday-Friday, first shift work schedule, leaving no
BPR support over weekends or evening shifts. Since review and approval support is not
available across all production shifts, we can conclude that this negatively impacts the
cycle time by creating delays, particularly over weekends, when the BPR sits and waits
for Monday to be reviewed.
In summary, we determine the major causes of wait time in this process to be:
" Geographical distance between work groups
e Prioritization of batches
* Batching of BPRs
e Limited resource coverage & resource bottlenecks
* Multiple reviews performed in series after production is completed
" Re-work (to be discussed in the next section)
3.2.1.2 Re-Work Root Causes
We observed a re-work rate of approximately 11% within the QA review step. This
means that approximately 11% of batches reviewed have some type of error which
requires the document to be sent back to manufacturing for correction, and then sent back
to QA for another review and approval.
We evaluated the historical data on errors in this production area. The QA area tracks all
errors received, and classifies each into one of four categories, as described in Table 5.
Table 5: Types of Errors
Type of Error Description
Missing Data Failing to fill in a required field
Wrong Data Transcription errors, inversed numbers, and general
"human" mistakes when copying & writing down data
Missing Attachments Attachments are not complete or missing
. CHandwriting ambiguity or for errors that operators
GMP Correction attempt to correct, but do not correct properly
Understanding what types of errors occur can help us pin-point true root cause of the
errors (and subsequent re-work). Table 6 lists the average percentages of various types of
errors, and Figure 7 displays this data graphically.
Table 6: Error Rate Analysis
Percentage of Percentage of Total
Total Errors (YTD) Errors (July Only)
Missing Data 15% 29%
Wrong Data 78% 71%
Missing Attachments 0% 0%
GMP Correction 7% 0%
Average Rates Average Rates
(YTD) (July Only)
Overall Error Rate 11% 11%
Right First Time rate 89% 89%
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Thus, we can see that "Wrong Data" makes up the bulk of errors (78% of YTD errors).
There is a small occurrence of "Missing Data" errors, and "Missing Attachments" and
"GMP Correction" errors occur rarely, if at all.
The data from this analysis is encouraging, due to the low rates of "Missing Data" and
"Missing Attachments", which show that the actual format of the BPR generally
facilitates correct execution of the document; in effect, if the format of the document
itself was confusing or unclear, we would expect much higher rates of "Missing Data" or
"Missing Attachment" errors. However, this also eliminates the "easy answer" of simply
re-formatting the BPR documentation to improve error rates.
To drive to root cause, we focus on analyzing the cause of "Wrong Data" errors. These
errors are made when operators make a mistake in copying data from one location to
another, such as inversing numbers or omitting a number in a sequence of numbers (such
as a lot number). These types of errors can generally be attributed to "human error"
causes, such as fatigue or inattention to detail. Additionally, highly repetitious entries or
unnecessary entries may increase the chances of "Wrong Data" errors.
In summary, we determine that the 11% re-work rate is due predominately to
transcription or other human errors in documentation, possibly caused by lack of
attention and fatigue, possibly caused by repetitious or unnecessary entries.
3.3 SOLVE PHASE
In the seek phase, we performed a detailed analysis to drive to root causes of the wait
times and re-work observed in the value-stream map of the overall documentation
process. The possible root causes are identified in Table 7.
Table 7: Summary of Root Causes of Re-Work and Delays
Causes of Delays Causes of Re-Work
" Geographical Distance Transcription &
other "human" errors
" Prioritization of Batches
e Batching of BPRs




3.3.1 DETERMINE POSSIBLE SOLUTIONS
At this point, the team sought to brainstorm and identify possible solutions that could
solve many or all of these likely root causes.
In Quick Response Manufacturing: A Companywide Approach to Reducing Lead Times,
Rajan Suri discusses that there is a traditional belief that resources will have to work
harder, faster and longer to get jobs done quicker (17). However, Suri counters that one
of the pillars of Quick Response Manufacturing (QRM) is to seek new ways of
completing a job, with the focus on reducing time, instead of just doing the same process
faster. Suri suggests completely rethinking how you organize processes and work. Suri
suggests:
"Conventional sequences of... operations are sometimes in place because
of technical process requirements, and at other times because of attempts
to maximize efficiency of the process. Challenging the second reason can
lead to new operations that are better for quick response (17)."
Thus, while the group did consider more traditional efficiency-improvement
solutions aimed at shortening cycle-time, the team focused on re-thinking the
process to determine if a more radical re-thinking of the process could result in
more significant future improvements.
Additionally, in The Lean Six Sigma Pocket Toolbook, George, Rowlands, Price,
and Maxey suggest systematically considering parallel and series events when
focusing on time reductions (19). The book defines serial events as activities that
cannot be performed while another task is performed, and parallel events as those
which could be performed while another is on-going. The team was challenged to
re-think their established practices of performing reviews and approvals in series,
and to creatively invent ways to perform these reviews and approvals in parallel.
Table 8 details the various solutions discussed by the team to address the root causes of
delays.
Table 8: Possible Solutions for Root Causes of Delays
Table 9 details the possible solutions to solve the issue of re-work.
Cause ofDelay Possible Solutions Comments
Will improve cycle-times by shortening distances
Move all resources into the production area between groups & improving working relationships
Geographical Distance between groups
Create a mechanism to move BPR between work Improves cycle-time by creating a set process to
groups ensure move BPRs from one work group to another
Improves overallcycle-time by frcing allBPRs to be
Prioritization ofBatches Set prioritiation (such as FIFO) addressed in order, no bnger allow some BPRs to sit
xile while others are expedited
Batching of BPRs Cease the practice of batching BPRs Improves cycle-time by allowing Quality Assurance to
review and approve BPRs when they are received
Hre more resources May improve cycle-tims by creating a largrLimited resource coverage & resource resource poolto review and approve
bottlenecks Cross tra resources to performmliple fctions e e m vingpossible botm ck
at key steps
Perform "Real Tim Review" (ie., quality reviewers Improves cycle-times by moving manufacturing and
Multiple reviews performed in series and approvers circulate out on the production floor and quality review and approval steps to occur concurrent
after production review pages or sections of the BPR as they are with production
completed)
Table 9: Possible Solutions for Root Causes of Re-Work
Cause of Re-work Possible Solutions Comments
Transcription & other "human" errors Automate the process (e-BPRs) Inproves error rate by removing manual
data collection steps and safe-guarding
against typos and other human errors
Remove unnecessary fields & repeated data May reduce error rate by reducing the
number of entries operators must fill out
Improve training Improved training may be able to
encourage operators to have better
attention to detail
Perform "Real Time Review" This will improve the error rate by providing
real-time feedback to operators while they
are still on the process floor, improving their
future performance
It should be noted that due to the complex nature of preventing "human error", an
alternate solution would be to focus on catching errors earlier, instead of later. The
concept of Real Time Review provides a means to catch errors quickly, if they do in fact
occur.
3.3.2 CLASSIFY SOLUTIONS
Many solutions were discussed; some ranged from easy, simple solutions that could be
implemented immediately (such as setting prioritization) to costly, more elaborate
solutions that would take significant time and resources to implement (such as e-BPR
systems). In order to assess the solutions that would be the most cost-effective to the
business, all the solutions were evaluated in respect to cost and potential impact, as
showcased in Figure 8 below.
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Thus, we can see that the proposed solutions of ceasing bundling, creating a mechanism
for moving the BPR from one work group to another, setting prioritization, and
implementing Real Time Review are considered the highest impact and lowest cost
solutions. We also note that Real Time Review was considered a solution for both our
primary issues (both re-work and cycle-time), making this a particularly attractive
solution.
3.3.3 SELECT RECOMMENDATIONS
Based on this analysis, we decided to move forward with implementation of Real Time
Review. Under the theoretical concept of real-time review, the manufacturing and quality
reviewers and approvers would spend time out on the manufacturing floor, and would
review sections or pages of the BPR as they were completed. Thus, at the end of
manufacturing, the majority of the document would have been already reviewed by both
the reviewers and the approvers, facilitating the final approval sign-offs after the
completion of the batch.
Real Time Review was selected as the primary solution to be implemented for several
reasons. First, Real Time Review was something that could be implemented almost
immediately at no cost; existing resources simply needed to begin doing their work out
on the production floor, instead of at their desks. It should also be noted that there were
no regulatory barriers to implementing Real Time Review. Secondly, the concept of Real
Time Review essentially accomplished the other suggested high-impact, low-cost
solutions of ceasing bundling, creating a mechanism for moving the BPR from one work
group to another, and setting prioritization. In order for quality resources to review on the
floor, they would have to cease bundling, since reviewers can no longer wait and review
multiple BPRs at one time. Additionally, having the reviews occur out on the production
floor co-locates the various resources, which negates the need for a mechanism to move
the BPR from one work group to another. Finally, Real Time Review forces a First In,
First Out (FIFO) methodology for review, since the batches must be reviewed in-
progress.
Additionally, while many of the suggested solutions suggested drive to improve only
cycle-time or re-work rates, Real Time Review will address both issues. Implementing
Real Time Review would improve cycle-time by allowing production, review and
approval steps to occur simultaneously. Also, having the manufacturing reviews on the
floor will allow any errors to be caught immediately; ideally, the operator responsible
will still be on the floor and can make corrections immediately, negating the need for a
lengthy re-work process later on in the review cycle.
Also, having additional quality and manufacturing resources on the floor providing
reviews during production creates a more collaborative environment in which feedback
can be immediately given to operators, which may improve future work habits. Finally,
having quality assurance on the manufacturing floor allows them to be in close access to
data and subject matter experts, so any questions can be answered immediately, instead
of causing a delay.
Finally, Real Time Review is in alignment with current FDA guidance to build quality
into the process. In 2003, the FDA introduced a regulatory framework called Process
Analytical Technology (PAT) that is designed to voluntarily encourage development and
implementation of innovative pharmaceutical manufacturing and quality assurance
systems. PAT focuses on systems which analyze and control manufacturing through
timely measurement of critical quality attributes with the end-goal of ensuring final
product quality (21).
According to the FDA's Guidance for Industry: PAT- A Framework for Innovative
Pharmaceutical Development, Manufacturing, and Quality Assurance:
"The goal ofPA T is to understand and control the manufacturing
process... quality cannot be tested into products; it should be built-in or
should be by design. " (22)
The FDA goes on to state that the desired state of pharmaceutical manufacturing would
feature continuous real-time quality assurance. Furthermore, the FDA states that in order
to reach a state-of "built-in quality", pharmaceutical manufacturers should seek reduced
production cycle-times via on-line or in-line measurements and controls. The FDA also
indicates that "built-in quality" may be obtained by implementing real-time release,
which is defined as the ability to evaluate and ensure the acceptable quality of in-process
and/or final product based on process data (22). While much of the FDA's PAT
framework is intended to improve in-line processing monitoring equipment and
technology, the PAT framework can be viewed more broadly as a set of technology,
process and behavioral improvements intended to improve final product quality.
Real-Time Review is in alignment with the FDA's PAT framework. By encouraging
quality reviews on the floor, Real Time Review will help the area build quality into their
operational processes. Additionally, Real Time Review helps to move towards the FDA
suggestion to reduce cycle-times by leveraging real-time quality control. Finally, Real
Time Review will help NVD move towards a real-time release process. While Real Time
Review in no way meets all the goals outlined in the FDA's PAT framework,
implementation of Real Time Review will help NVD move towards PAT's end goal of
building quality into the system.
Overall, based on its low cost and high expected impact, as well as it's alignment with the
FDA's PAT framework, the team selected the implementation of Real Time Review as
the primary solution to improve re-work rates and decrease cycle-times.
3.3.1.1 Future Value-Stream Map
After a final recommendation was selected, we could use this recommendation to create a
future value stream map. This map can be used to visualize the future process, and help
us understand how much improvement may be possible, as well as show exactly how our
target goals can be achieved.
The future state value-stream map can be seen in Figure 9 below.
Figure 9: Future State Value Stream Map
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3.4.1 IMPLEMENT SOLUTIONS
Just selecting an appropriate solution isn't sufficient to drive to results; the solution must
be appropriately implemented in order to improve cycle-time and re-work rates. In
Managingfor Excellence, Bradford and Cohen caution:
"the highest-quality solutions are of little value if they won't be
implemented. Conditions have to be such that all the members are willing
to work together" (23)
While Real Time Review is a simple concept, it changes where and how resources
perform their work. There were major cultural barrier that had to be overcome in order to
gain an acceptable level of buy-in from the team in order to adequately implement the
solution.
3.4.1.1 Overcoming Cultural Barriers
As discussed in Section 2.3, Novartis Vaccines and Diagnostics is relatively young,
created from the acquisition of a struggling company. In many conversations with NVD
employees (many of whom formerly worked for Chiron), they expressed that Chiron has
operated its sites very independently, with little transfer of communication between the
sites. The concepts of sharing best practices or striving for operational excellence were
not concepts widely practiced across all Chiron employees. Since the acquisition, NVD
has worked to implement operational excellence across all the sites via their IQP
program. However, cultural change is a slow process, and at the time of this project, not
everyone at the site was familiar with the concepts of operational excellence or IQP.
None of the member of key my team had ever done an operational excellence project
before. Previously, the site had set goals, and had worked to meet these goals. At the time
of the project, the site goals for cycle-time and Right First Time were 34 days and >75%
respectively. As you may recall, our baseline metrics of 24.8 day cycle-time and 89%
Right First Time rates met the site goals. While management realized that the site
performance should be improved, the site goals had not yet been updated, and thus there
was little support for improving a process which was already easily exceeding the site
goals.
Additionally, the site was a non-English speaking site, so there was a considerable
language barrier between myself and many of the resources on my project teams; this
barrier was particularly apparent between me and the resources at a shop floor level.
Since the project was to be implemented on the shop floor, having clear understanding
between myself and the shop floor resources as well as appropriate buy-in and support
were crucial to project success.
Finally, the team had trouble seeing how this project would be implemented without
additional resources. Many resources seemed the think that the concept of Real Time
Review was great, but would necessitate the hiring of many more reviewers and
approvers to implement. We were constantly faced with complaints that with all the
current work, there was no way this additional project could also be implemented.
The team leveraged several tactics in order to create support and buy-in for the
implementation of Real Time Review.
In Making Common Sense Common Practice: Models for Manufacturing Excellence,
Moore describes an age-old tale about three quarry workers (24). When asked what they
are doing, the first one replies that he is pounding rocks. The second states he is working
hard in order to make a good life for his family. The third proudly shares that he is
creating a temple to his god. In fact, all three are doing the same job, but they have
different levels of motivation due to how they view their situation. Moore states that in
order for successful implementation, there must be a focus on creating and building a
sense of purpose for each team member. Moore also instructs that the first step in change
management is to articulate a compelling reason for change.
In order for the team to see how their actions were integral not only to the project, but
also to the site and the entire organization, the team brought in resources from site
management as well as the global IQP group. These project sponsors discussed how the
Real Time Review project was aligned with critical site and global goals to improve
process efficiencies. The purpose of this discussion was to help foster a stronger sense of
purpose for the team. Additionally, management was also able to speak to the fact that
site goals and expectations would change in the future to require faster cycle-times and
lower error rates, so that this project could be viewed as a pre-emptive way to meet future
goals and expectations, which helped articulate a compelling reason for change.
Additionally, we benchmarked with other biotech and pharmaceutical companies that had
implemented Real Time Review at their facilities with success. A current NVD employee
who had formerly worked at a plant that achieved cycle-times under 24 hours spoke to
the group about the process to implement Real Time Review at his former site and to the
successes of the project. By benchmarking, we strove to share stories of success and to
show that the concept of Real Time Review was not impossible.
Perhaps most importantly, we strove to show how implementing Real Time Review
would actually make every resource's work simpler, easier, and faster for them to
execute. We described that Real Time Review would catch issues early, which would
prevent resources from tracking down operators to make changes later on. We discussed
how doing reviews on the manufacturing floor would put the reviewers in close contact
with all associated documentation (such as logbooks, etc) and the people who actually
execute each step; thus, if the reviewer had any questions, they would not have to track
down the information, it would be readily available. We focused on showing how the
project would actually result in less work (not more), thus making it feasible with
existing resources.
Finally, we identified that gaining sufficient buy-in for permanent implementation of
Real Time Review was likely not feasible within the confines of the six-month project
timeline. Thus, we focused on running a Real Time Review pilot. The pilot would allow
us to change behaviors temporarily, and assess if the changes were successful. Then,
based on the level of success (or failure) achieved, the team could modify the solution for
permanent implementation. The pilot allowed us to test Real Time Review in a low-risk
environment. Thus, while we were not able to obtain sufficient buy-in for a permanent
change, we were able to establish enough buy-in to test and validate the concept via a
pilot.
3.4.1.2 Pilot Planning
Ample time and consideration was given to planning the pilot. It was understood that
since the team was struggling to envision themselves performing Real Time Reviews, we
needed to make the transition very simple in order to prevent confusion and distress.
Additionally, as discussed previously, review and approval resources were not available
across all production shifts, so a plan was needed to ensure that if reviews were not
possible real-time, that they occurred as quickly as possible, ideally the morning of the
following business day.
In order to create this plan, we created a day-by-day schedule. The schedule tracked the
expected manufacturing schedule for several steps. It also detailed when "on-the-floor"
reviews could be performed, and set guidelines for when final reviews & approvals
should be done to drive towards 24-hour cycle-times. A simplified representation of this
daily schedule can be seen in Appendix A.
This schedule helped in simplifying logistics, and also assisted in helping the team
visualize how Real Time Review could actually work. Instead ofjust telling the resources
to go do Real Time Review, and let them struggle to conceptualize what exactly that
would mean, we created a detailed schedule which allowed them to truly understand the
behavior changes that Real Time Review would require. Additionally, in Making
Common Sense Common Practice, Moore states that one of the key ways to align the
organization is to make it easy to do it right (24). By creating a step-by-step schedule, we
made the expectations very clear, and made it easier for the review resources to "do it
right."
Next, we realized that we needed a way to track data during the pilot. Current
documentation accompanying the BPR included a sign-off sheet, with a single line for
each reviewer or approver to indicate that they had reviewed the document in its entirety.
Now, the reviewers and approvers were expected to review the document in pieces on the
floor as they were completed. Thus, we needed a worksheet that could track what BPR
portions had been previously reviewed to ensure no sections were skipped (and no
sections were re-reviewed). Additionally, we wanted this sheet to track real-time cycle-
time and Right First Time data, so that we could evaluate our progress, and identify areas
that still needed improvement in the future.
We created a color-coded tracking sheet that both tracked the data required for analysis,
and also assisted the resources track their progress on reviews. A representation of this
data sheet is located in Appendix B.
Finally, we held an interactive training with all reviewers and approvers to train them on
the behavior changes required by the pilot, as well as how to utilize the data sheet. The
trainings were held in both English and the native language of the area to ensure that all
resources could understand the training, and so that questions could be adequately
understood and addressed.
Via tools such as a tracking sheet, daily schedule, and interactive training sessions, we
worked to clarify the expectations to the reviewers, making it "easy to do it right".
3.4.1.3 Pilot Execution
The pilot was executed in a product area of one of Novartis Vaccines and Diagnostics'
manufacturing facilities for a period of two weeks. In this time, 43 BPRs were reviewed
under the Real Time Review format, and detailed data from each batch was acquired and
recorded. Results of the pilot will be discussed in Section 3.4.2.
During the pilot, daily feedback meetings were held with the reviewers and approvers.
The meetings allowed questions to be asked and answered quickly, and also allowed the
team to modify the data collection sheet to be more user-friendly. The daily feedback
meetings were instrumental to the success of the pilot.
3.4.2 FINAL RESULTS
As mentioned in Section 3.4.1, the pilot was executed across a period of two weeks and
had a sample size of 43 BPRs. The results from the pilot, as well as the previous baseline
and project goals, are summarized in Table 10.
Table 10: Pilot Results, as Compared to Baseline and Targets
Pilot Results Blue-Sky
(Average) Baseline Project Target Goal
Cycle-Time 2. 1 days 24.8 days 7 days I day
Right First
Time 95% 89% 95% 100%
There was considerable improvement in both cycle-time and Right First Time rates in the
pilot. We will discuss each individually.
3.4.2.1 Cycle-Time Results
We can see that the average cycle-time observed in the pilot was 2.1 days. This is a 92%
improvement from the baseline of 24.8 days. 2.1 days is well below the project target of 7
days, although it does not yet meet the Blue Sky Goal of I day.
To further explore the cycle-time results, we analyzed the real-time data gathered via the
pilot, as shown in Table 11.
Table 11: Analysis of Real-Time Review Data from Pilot
Cumulative Activity
Activity Step Time Total Step Cycle Time* Wait Time
(Value Added Time)
Manufacturing 30.8 mi 1171.6 min 1140.8 min
Review (19.5 hrs) ** (19.0 hrs) **
Manufacturing 177 min 384.4 min 366.7 min
Approval (6.4 hr) (6.1 hrs)
984.3 min 948.9 minQAReview 35.4mi (16.8 hr) (15.8 hr)
493.3 min 490.7 minQA Approval 2.6 mn (8.2 hr) (8.2 hr)
*Note: Total Step Cycle-Time is defined as the time to perform the activity, as well as any
additional wait time required prior to execution of the step.
**Note: The Manufacturing Review Step also includes reconciliation and other required
post-manufacturing steps, which extend the cycle-time..
From Table 10, we can see that the cumulative activity time (or value added time) for
each step ranges from 35.4 minutes for QA review, to 2.6 minutes for QA approval.
Some of these values, particularly the values associated with review times, are markedly
different from the values discussed in the baseline value-stream map from July (shown in
Figure 5). Original estimates had placed manufacturing review at 3 hours, and QA review
at 4 hours. Each approval was expected to take 15 minutes.
While the easy access of information, materials, and subject matter experts on the floor
likely did decrease the activity times for these various steps, it is also likely that the
original estimates were inflated. As previously discussed, many of the activity times
(including reviews and approvals) were estimated based on interviews with the reviewers
and approvers. It is possible that the previous method of performing the reviews in office-
space environments created a higher likelihood of distraction or interruption, lengthening
the overall time to complete the task, and thus increasing the perceived activity time from
the viewpoint of the review or approver. This would help explain the marked differences
between the estimated activity (or value-added) times in Figure 5 and the times directly
observed during the pilot.
The data indicate that the sum of the value-added time is 86.5 minutes. Thus, we can see
that the Blue Sky goal of post-production review in under 24 hours is feasible in the
future, if the team continues to evaluate methods to decrease non-value added wait times
in the process.
Next we evaluate the total step cycle-times and wait times. We can see that in all cases,
the wait times are still significantly longer than the activity times. In the pilot, the wait
times were generally caused by delaying the next step either overnight or over a weekend
due to lack of review and approval resources on night and weekend shifts. While the
results observed are an excellent improvement, the analysis shows there is still wait time
in the system that can be targeted in the future in order to achieve the 24-hour cycle-time
goal.
Next, we analyzed the variability of the data observed in the pilot, as shown in Table 12.
Table 12: Analysis of Variance of Real-Time Review Data from Pilot
QA
Manufacturing Manufacturing QA Review Approval Overall Post-
Review Step Approval Step Step Cycle Step Cycle Production
Cycle Time Cycle Time Time Time Cycle-Time
(Minutes) (Minutes) (Minutes) (Minutes) (Minutes)
Minimum value 10.0 10.0 0.0 * 7.0 333.0
25% Percentile 365.0 25.0 100.5 110.5 1382.5
75% Percentile 1095.0 242.5 465.5 382.5 4433.5
Maximum value 4200.0 3085.0 5900.0 4614.0 7051.0
Standard
Deviation 1191.2 762.9 1669.2 953.5 1861.3
Mean 1171.6 384.4 984.3 493.3 3003.2
*Note: Indicates this step was actually completed prior to manufacturing approval,
leading to a cycle-time of zero.
We can see that there is significant variability in each individual process step; in each
step, the standard deviation is larger than the mean itself, indicating skew, which can be
seen most clearly by comparing the very short minimum value times with the extended
maximum value times. As previously mentioned, there are times when the BPR must
wait for the following morning, or the following Monday, before progressing through the
process.
We can conclude that each step has a high level of variance; in the future, combating this
variance will be instrumental in creating a process which can consistently provide cycle-
times under 1 day.
In particular, we can see that there is a high variation observed in the Manufacturing
review portion of the cycle-time. It also has the highest average step cycle-time of 1171.6
minutes (or 19.5 hours). However, this step also includes the reconciliation and cleaning
steps; this means that the review cannot be completed until cleaning, reconciliation, and
other activities have been completed, which can inflate the cycle-time. Future work could
be done to streamline this entire process, but since reconciliation and cleaning are
necessary, value-enabling activities, this may not necessarily be the best target for future
cycle-time reductions.
There is also a high variance observed in the QA review step cycle-time, which has the
second-highest average step cycle-time of 984.3 minutes (or 16.8 hours). Unlike the
aforementioned case with production cycle-time, this step is not dependant on any
external activities, so the wait time associated with this step should be aggressively
targeted in the future.
3.4.2.2 Right First Time Results
As seen in Table 10, the Right First Time rate also improved during the pilot. The Right
First Time rate was 95% during the pilot, a 55% improvement from the baseline of 89%.
This result was within the project target of 95%, but does not yet reach our Blue Sky
Goal of 100%.
Of the 43 data points obtained, 41 of them were indeed Right First Time. Both errors
were "Wrong Data" errors; these are historically the most prevalent errors, as shown in
Figure 7.
It should be noted that this trial utilized a small sample size, and therefore each individual
error occurrence has a significant weight on the final Right First Time results. For
example, if one additional error had occurred, the RFT rate would have fallen to 93%
(which is below the project goal). Alternately, if there had been one less error observed in
the trial, the Right First Time rate would have been nearly 98%. Due to the small sample
size, there is not enough statistical evidence to support that a 95% Right First Time rate
will necessarily remain over time. Indeed, assuming a Poisson Process, if one observed
two errors, a 95% upper confidence bound will exceed six errors, and thus one could not
assume a true RFT rate above 85%. This RFT metric should be carefully observed and
evaluated in the future.
3.4.2.2 Discussion of Results
The results of this pilot are considered positive. Both the cycle-time and Right First Time
rates met the project goals during the pilot period.
Furthermore, feedback from the reviewers and approvers was positive. Feedback
indicated that the reviewers and approvers appreciated the new process. While the
reviewers expressed initial discomfort with the change, after they became accustomed to
the new process, the reviewers and approvers appreciated the new method, since it
allowed them easier access to critical information on the manufacturing floor.
Additionally, both quality control and manufacturing resources noted that the new
process forced them to work together more closely, which created an environment of
increased understanding and collaboration.
3.5 PROJECT CLOSEOUT
After the pilot, a "Lessons Learned" session was held to better understand the positive
and negative aspects of the project. The team defined the following as positive attributes
of the project:
- Pilot forced QA and Manufacturing to work together, which was beneficial for
both groups
- Pilot forced QA on the floor more, which helped them better understand the
process
- Pilot process improved relationship between QA and Manufacturing
- Pilot improves document housekeeping in the area
The team identified the following areas as being areas for future opportunity:
- Support is needed across all production shifts
- Pilot only looked at one area, additional pilots should be run in other process
areas as well
- Having approvers and reviewers permanently on the floor (instead ofjust
circulating periodically) would improve the process
- Pilot did not address current resource bottlenecks
From these lessons learned and the data analysis, recommendations for the future were
identified and communicated. This is discussed in more detail in Section 4.2.
At the end of this project, all the data, charts, diagrams and other information was turned
over to the area to ensure knowledge transfer of the project details.
Going forward, the area where the pilot was conducted appreciated the results and the
new, more efficient process, and decided to maintain the behaviors adapted during the
pilot. From the end of the pilot until the end of 2009, the area had maintained the cycle-
times and Right First Time rates observed in the pilot.
Finally, in his book Making Common Sense Common Practice, Moore discusses that
ensuring rewards is integral to aligning the organization for the future (24). Under that
advice, the project was closed out with a celebratory event attended by all pilot
participants and site management. We shared information about our successes, and had
some drinks and snacks and socialized. The event was aimed at ensuring that all
participants knew their hard work was appreciated.
CHAPTER 4: CONCLUSIONS & RECOMMENDATIONS
4.1 CONCLUSIONS
In summary, creating a value-stream map of a documentation process allowed us to
identify the true sources of delay and rework in the process. Value-stream mapping
proved to be a useful tool in order to streamline a regulated business process. By utilizing
a value-stream map, we were able to make decisions based on data, instead of on
assumptions or "gut feelings". By closely examining data, we were able to identify the
root causes of delays and re-work, and came up with a solution (Real Time Review) that
combated both issues.
Real Time Review is simple: the reviewers and approvers simply do their tasks out on the
manufacturing floor instead of at their desk. The solution focuses on making activities
that were former performed in series into activities that can be performed in parallel with
manufacturing, thereby reducing the overall cycle-time. Additionally, the solution
promotes higher Right First Time rates by performing checks on the floor, allowing
reviewers to provide direct feedback to operators.
Although the solution is conceptually simple, implementation of any project requires
buy-in from the entire team to ensure success. Significant focus was placed on gaining
buy-in from the team. Future-state maps and day-by-day schedules were created to help
the team visualize the future state, and data collection sheets and daily feedback meetings
helped the reviewers and approvers perform their new behaviors more easily. During a
two-week pilot of Real Time Review, the team saw a 92% improvement in cycle-time
and a 55% improvement in Right First Time Rate. An implementation strategy focused
on obtaining buy-in, leveraging a temporary pilot, and creating detailed scheduling and
tracking tools proved useful in overcoming cultural barriers and allowing a successful
implementation.
Careful analysis of the pilot data and lesson learned feedback resulted in several areas for
future improvement, which are detailed in Section 4.2.
4.2 FUTURE RECOMMENDATIONS
There are several areas of future opportunity for Novartis Vaccines and Diagnostics to
further improve their batch record cycle-times and Right First Time rates. These future
recommendations have been organized into short-term and longer-term
recommendations.
4.2.1 SHORT TERM RECOMMENDATIONS
In the short term, Novartis Vaccines and Diagnostics should seek to implement more
solutions that are low-cost and high-impact, like Real Time Review. A first
recommendation would be to create work schedules similar to the one utilized in the pilot
for all areas across NVD manufacturing to encourage reviews and approvals to be done
on the manufacturing floor in all areas. The pilot showed this philosophy is capable to
drastically reducing cycle-times and improving Right First Time rates. Additionally,
encouraging reviewers and approvers to work out on the manufacturing floor improves
their knowledge of their processes, and encourages collaboration between quality
assurance and manufacturing. In the future, this improved working relationship between
the two groups could improve communication and create better efficiencies across many
different processes, not just the batch record approval process. Finally, the concept of
real-time quality assurance is aligned with current PAT guidance from the FDA.
Additionally, NVD can cross-train its reviewers and approvers so ensure that there are
fewer bottlenecks in resources, particularly at the approver step. This will ensure that
unforeseen events, such as sickness, vacation, etc does not negatively impact the cycle-
times moving forward.
Another recommendation would be to simplify the BPR documentation. First, all
unnecessary fields should be removed to decrease the likelihood of making an entry error
or other documentation mistake. Additionally, the document should be revised to
facilitate real-time review. There are several ways this can be done; one solution would
be to place a sign-off for manufacturing and quality assurance on the bottom of each
section or page, allowing resources to actually approve by section or page, instead of
tracking their work and then signing once at the completion of the batch.
Finally, NVD should focus on ensuring that the Right First Time and cycle-time goals
and current metrics are well understood throughout the organization. These metrics
should be tracked regularly and communicated out through the operator level to ensure
the organization has sufficient alignment and focus to sustain the successes observed in
the pilot.
4.2.2 LONGER TERM RECOMMENDATIONS
In the longer term, NVD should focus on making strategic investments that will improve
both efficiency and compliance of their batch records processes. One such investment
would be moving review and approval resources to permanently sit on the manufacturing
floor, or at least in the same building. This would greatly facilitate Real Time Review,
and would also help foster collaboration between the resources on other processes as
well.
NVD should also evaluate the review and approval requirements. Currently, there are
four separate persons who must review and sign each BPR. As we encourage these
reviews to occur in tandem out on the floor with the operators, we can see that it is likely
that some of the reviews will become non-value added over time, and can be eliminated
(with the exception of quality assurance review and approval, which is required per the
CFR). A longer term plan to phase-out manufacturing review and/or approval could be
another way to continue to improve efficiencies.
One issue during the pilot was the lack of review and approval resource availability on
evening and weekend shifts. If NVD truly wants to pursue a 24-hr cycle-time for BPR
review and approval, there must be resources for review and approval across all
manufacturing shifts.
Finally, as a long-term plan, NVD should continue to investigate the implementation of
an electronic BPR (or e-BPR) system. Such a system would decrease the error rate by
preventing transcription and other errors, and also improves compliance by preventing
the advancement of the process if any critical parameters have not been met. The
electronic signatures required by an e-BPR system can help continue to drive down the
cycle-time. Currently, implementations of e-BPR systems are quite costly, but this
solution should be considered for the longer-term.
4.2 FINAL SUMMARY
In summary, the use of value-stream mapping was a useful tool in order to visualize a
documentation process. The value-stream map allowed the team to identify root causes of
re-work and waste and develop solutions to combat these issues. With the
implementation of Real Time Review, the team was able to observe a 55% increase in
Right First Time rates, and a 92% decrease in cycle-times.
In order to further improve Right First Time and cycle-time rates across the company,
NVD should implement Real Time Review across all of its manufacturing areas.
Additionally, NVD should focus on short-term and long-term goals to further advance
documentation efficiency and compliance. Some short-term goals would include cross-
training resources, streamlining documentation, and ensuring appropriate metrics are
tracked and communicated. Some longer term goals would include permanently moving
review and approval resources onto the manufacturing floor, removing manufacturing
review signatures, ensuring there are review and approval resources across all
manufacturing shifts, and implementing an electronic BPR system.
By focusing on some of these short and longer term goals, NVD can continue to improve
their BPR documentation review process efficiency and compliance.
APPENDICES
Appendix A: Daily Real Time Review Schedule













































































Appendix A: Real Time Review Schedule (page 2)
Appendix B: Data Collection Sheet
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